

3rd edition

Unmet challenges in high risk hematological malignancies: from benchside to clinical practice

Turin, September 21-22, 2023

Starhotels Majestic

Scientific board:

Marco Ladetto (Alessandria)

Umberto Vitolo (Candiolo-TO)



AUSPICES

UNIVERSITÀ DEL PIEMONTE ORIENTALE

ISTITUTO DI CANDIOLO - FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA - IRCCS

AZIENDA OSPEDALIERA DI ALESSANDRIA SANTI ANTONIO E BIAGIO E CESARE ARRIGO

UNIVERSITÀ DI TORINO

FIL - Fondazione Italiana Linfomi

GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo,
cellule staminali emopoietiche e terapia cellulare

SIE - Società Italiana di Ematologia

SIES - Società Italiana di Ematologia Sperimentale

RETE ONCOLOGICA DEL PIEMONTE E DELLA VALLE D'AOSTA

FACULTY

Emanuele	Angelucci	Genoa, Italy	Won Seog	Kim	Seoul, Korea
Stephen M.	Ansell	Rochester, USA	Shahram	Kordasti	London, UK
Luca	Arcaini	Pavia, Italy	Marco	Ladetto	Alessandria, Italy
Monica	Balzarotti	Rozzano (MI), Italy	Armando	Lopez-Guillermo	Barcelona, Spain
Nicolas	Boissel	Paris, France	Stefano	Luminari	Reggio Emilia, Italy
Benedetto	Bruno	Turin, Italy	Federico	Lussana	Bergamo, Italia
Alessandro	Busca	Turin, Italy	Maurizio	Martelli	Rome, Italy
Elias	Campo	Barcelona, Spain	Massimo	Massaia	Cuneo, Italy
Carmelo	Carlo-Stella	Rozzano (MI), Italy	Pau	Montesinos	València, Spain
Fabrizio	Carnevale Schianca	Candiolo (TO), Italy	Tahla	Munir	Leeds, UK
Bjoern	Chapuy	Berlin, Germany	Grzegorz	Nowakowski	Rochester, USA
Annalisa	Chiappella	Milan, Italy	Bruno	Paiva	Pamplona, Spain
Sabina	Chiaretti	Rome, Italy	Stefano A.	Pileri	Milan, Italy
Daniela	Cilloni	Turin, Italy	Christiane	Pott	Kiel, Germany
Antonio	Cuneo	Ferrara, Italy	Umberto	Ricardi	Turin, Italy
Antonio	Curti	Bologna, Italy	Luigi	Rigacci	Rome, Italy
Maria	Diez Campelo	Salamanca, Spain	Davide	Rossi	Bellinzona, Switzerland
Hermann	Einsele	Würzburg, Germany	Giuseppe	Saglio	Orbassano (TO), Italy
Thierry	Facon	Lille, France	Valeria	Santini	Florence, Italy
Andres J.M.	Ferreri	Milan, Italy	Stephen J.	Schuster	Philadelphia, USA
Simone	Ferrero	Turin, Italy	Catherine	Thieblemont	Paris, France
Robin	Foà	Rome, Italy	Adriano	Venditti	Rome, Italy
Roberto	Freilone	Turin, Italy	Carlo	Visco	Verona, Italy
Gianluca	Gaidano	Novara, Italy	Umberto	Vitolo	Candiolo (TO), Italy
Francesca	Gay	Turin, Italy	Maria Teresa	Voso	Rome, Italy
Paolo	Ghia	Milan, Italy	Pier Luigi	Zinzani	Bologna, Italy
Guido	Gini	Ancona, Italy			
Georg	Hess	Mainz, Germany			

09.30 **Welcome and introduction**
M. Ladetto, U. Vitolo and Scientific Authorities

10.00-11.30 Hodgkin Lymphoma and T-cell Lymphoma
Chairmen: U. Ricardi, L. Rigacci

10.00 How I treat high-risk Hodgkin lymphoma in first line
S.M. Ansell

10.20 Novel treatments in relapsed/refractory Hodgkin lymphoma
P.L. Zinzani

10.40 Pathobiology of nodal peripheral T-cell lymphoma
S.A. Pileri

11.00 **How I treat high-risk T-cell lymphomas**
W.S. Kim

11.20 Panel discussion

11.30-12.45 Mantle Cell Lymphoma

Chairmen: M. Balzarotti, M. Martelli

11.30 Biological identification of high-risk mantle cell lymphoma
E. Campo

11.50 How I treat high-risk mantle cell lymphoma in first line
G. Hess

12.10 How I treat relapsed/refractory mantle cell lymphoma
and new perspectives with CAR-T therapy
C. Visco

12.30 Panel discussion

12.45-13.45 *Lunch*

13.45-15.00 Large B-cell Lymphoma

Chairmen: A. Chiappella, A.J.M. Ferreri

13.45 Biological stratification of LBCL: are we ready to use it to tailor the therapy?
B. Chapuy

14.05 How I treat high-risk LBCL in first line
G. Nowakowski

14.25 Novel immunotherapies in relapsed/refractory DLBCL
C. Carlo-Stella

14.45 Panel discussion

15.00-15.30 **LECTURE I**

Chairman: *U. Vitolo*

Emerging immunotherapy in B-cell lymphomas:
the role of bispecific antibodies
C. Thieblemont

15.30-17.00 **Indolent Lymphoma**

Chairmen: *G. Gini, S. Luminari*

15.30 Biological of high-risk FL
C. Pott

15.50 How I treat high-risk FL in first line
S. Ferrero

16.10 How I treat high-risk relapsed/refractory follicular lymphoma
A. Lopez-Guillermo

16.30 How I identify and treat high-risk marginal zone lymphoma
L. Arcaini

16.50 Panel discussion

17.00-17.30 **LECTURE II**

Chairman: *B. Bruno*

CAR-T in multiple myeloma: therapeutic and timing
H. Einsele

17.30-18.45 **Chronic Lymphocytic Leukemia**

Chairmen: *A. Cuneo, M. Massaia*

17.30 Biology of high-risk CLL
D. Rossi

17.50 How I treat high-risk CLL in 2023
P. Ghia

18.10 How I treat high-risk relapsed/refractory CLL
T. Munir

18.30-18.45 Panel discussion

08.30-09.45 Multiple Myeloma

Chairmen: B. Bruno, R. Freilone

- 08.30 Biology of high-risk multiple myeloma or the role of minimal residual disease in multiple myeloma
B. Paiva
- 08.50 How I treat young high-risk multiple myeloma patients
F. Gay
- 09.10 The challenging treatment of elderly multiple myeloma patients
T. Facon
- 09.30 Panel discussion

09.45-11.00 Acute Lymphoblastic Leukemia

Chairmen: A. Busca, F. Carnevale Schianca

- 09.45 Biology of high-risk ALL
S. Chiaretti
- 10.05 Modern approaches as first line treatment of young adults and elderly patients with acute lymphoblastic leukemia
N. Boissel
- 10.25 CAR-T in adult ALL
F. Lussana
- 10.45 Panel discussion

11.00-11.30 LECTURE III

Chairman: R. Foà

**Worldwide disparity of access to clinical trials
and novel treatments in clinical practice**
G. Gaidano

11.30-12.40 Myelodysplastic Syndrome

Chairmen: D. Cilloni, V. Santini

11.30 The immune system in MDS: a friend or an enemy?
S. Kordasti

11.50 New approaches for treatment of MDS
M. Diez Campelo

12.10 Role of transplantation in high-risk MDS
E. Angelucci

12.30 Panel discussion

12.40-13.40 *Lunch*

13.40-14.10 LECTURE IV

Chairman: M. Ladetto

**Potential opportunities to overcome resistance to CAR-T therapy
in diffuse large B-cell lymphoma**
S.J. Schuster

14.10-15.20 Acute Myeloblastic Leukemia

Chairmen: G. Saglio, A. Venditti

14.10 Therapy related AML
M.T. Voso

14.30 Treatment of high-risk cytogenetic AML
P. Montesinos

14.50 Immunotherapy in AML and BPDCN
A. Curti

15.10 Panel discussion

15.20-15.30 Closing remarks

M. Ladetto, U. Vitolo

With an unrestricted educational grant of:



Miltenyi Biomedicine

abbvie

 **Bristol Myers Squibb™**

janssen  **Oncology**
PHARMACEUTICAL COMPANIES OF 

 **MENARINI Stemline**

GENERAL INFORMATION

REGISTRATION

Registration is available at www.ercongressi.it - section "I nostri congressi/anno 2023"

The registration fee includes: conference kit, participation in the scientific sessions, certificate of attendance, coffee break, lunch, slides of the meeting.

MEETING VENUE

Starhotels Majestic

Corso Vittorio Emanuele II, 54

10123 Torino, Italy

Tel. +39 011 539153

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828- 376685.
- No. 9,8 CME credits for Physicians (Haematology, Oncology, Internal Medicine) and Biologists.
- Educational objective: "linee guida-protocolli-procedure".

OFFICIAL LANGUAGE

English

BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants and speakers will be given a badge which must be worn in order to be admitted to the scientific sessions.

A certificate will be given to all participants at the end of the meeting.

SCIENTIFIC BOARD

Marco Ladetto MD

Associate Professor in Haematology
University of Eastern Piedmont Amedeo Avogadro
S.S. Antonio and Biagio and Cesario Arrigo Hospital
Via Venezia, 16 - 15121 Alessandria, Italy

Umberto Vitolo MD

Hematology Consultant
Candiolo Cancer Institute - FPO-IRCCS
Strada Provinciale, 142 - 10060 Candiolo (TO), Italy

SCIENTIFIC COMMITTEE

Prof. Benedetto Bruno - Torino

Prof. Gianluca Gaidano - Novara

Prof. Massimo Massaia - Cuneo

Prof.ssa Valeria Santini - Firenze

Prof. Adriano Venditti - Roma

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy

Phone +39 051 4210559 - Fax +39 051 4210174

E-mail: ercongressi@ercongressi.it

www.ercongressi.it